Discovery of pyridone-containing imidazolines as potent and selective inhibitors of neuropeptide Y Y5 receptor

Bioorganic and Medicinal Chemistry

Volumn 17, Issue 16, 2009, Pages 6106-6122

  Ando, Makoto ^a   Sato, Nagaaki ^a   Nagase, Tsuyoshi ^a   Nagai, Keita ^a   Ishikawa, Shiho ^a   Takahashi, Hirobumi ^a   Ohtake, Norikazu ^a   Ito, Junko ^a   Hirayama, Mioko ^a   Mitobe, Yuko ^a   Iwaasa, Hisashi ^a   Gomori, Akira ^a   Matsushita, Hiroko ^a   Tadano, Kiyoshi ^a   Fujino, Naoko ^a   Tanaka, Sachiko ^a   Ohe, Tomoyuki ^a   Ishihara, Akane ^a   Kanatani, Akio ^a   Fukami, Takehiro ^a  

^a BANYU PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Anti obesity; Imidazoline class; Neuropeptide Y Y5 receptor; Y5 antagonist

Indexed keywords

1 (DIFLUOROMETHYL) 5 [4 (4 FLUOROPHENYL) 4 (6 FLUOROPYRIDIN 3 YL) 5 METHYL 4,5 DIHYDRO 1H IMIDAZOL 2 YL]PYRIDIN 2(1H) ONE; GLYCOPROTEIN P; IMIDAZOLINE DERIVATIVE; MK 557; NEUROPEPTIDE Y RECEPTOR; NEUROPEPTIDE Y Y5 RECEPTOR INHIBITOR; PYRIDONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; FOOD INTAKE; MALE; MONKEY; MOUSE; NONHUMAN; RAT; REACTION OPTIMIZATION; RECEPTOR OCCUPANCY; STATISTICAL SIGNIFICANCE; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-OBESITY AGENTS; DOGS; DRUG DISCOVERY; HUMANS; IMIDAZOLINES; MICE; P-GLYCOPROTEIN; PYRIDONES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NEUROPEPTIDE Y; STRUCTURE-ACTIVITY RELATIONSHIP;

CANIS FAMILIARIS; MUS; RATTUS;

EID: 68149108470     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2009.05.069     Document Type: Article

References (35)

1. Tatemoto K., Carlquist M., and Mutt V. Nature 296 (1982) 659
2. Kalra S.P., Dube M.G., Sahu A., Phelps C.P., and Kalra P.S. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 10931
3. White J.D., Olchovsky D., Kershaw M., and Berelowitz M. Endocrinology 126 (1990) 765
4. Sanacora G., Kershaw M., Finkelstein J.A., and White J.D. Endocrinology 127 (1990) 730
5. Kesterson R.A., Huszar D., Lynch A.A., Simerly R.B., and Cone R.D. Mol. Endocrinol. 11 (1997) 630
6. Guan X.-M., Yu H., and Van der Ploeg L.H.T. Mol. Brain Res. 59 (1998) 273
7. Stanley B.G., Kyrkouli S.E., Lampert S., and Leibowitz S.F. Peptides 7 (1986) 1189
8. Erickson J.C., Hollopeter G., and Palmiter R.D. Science 274 (1996) 1704
9. Blomqvist A.G., and Herzog H. Trends Neurosci. 20 (1997) 294
10. Sato N., Takahashi T., Shibata T., Haga Y., Sakuraba A., Hirose M., Sato M., Nonoshita K., Koike Y., Kitazawa H., Fujino N., Ishii Y., Ishihara A., Kanatani A., and Fukami T. J. Med. Chem. 46 (2003) 666
11. Ishihara A., Kanatani A., Mashiko S., Tanaka T., Hidaka M., Gomori A., Iwaasa H., Murai N., Egashira S., Murai T., Mitobe Y., Matsushita H., Okamoto O., Sato N., Jitsuoka M., Fukuroda T., Ohe T., Guan X., MacNeil D.J., Van der Ploeg L.H.T., Nishikibe M., Ishii Y., Ihara M., and Fukami T. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 7154
12. Kanatani A., Mashiko S., Murai N., Sugimoto N., Ito J., Fukuroda T., Fukami T., Morin N., MacNeil D.J., Van der Ploeg L.H.T., Saga Y., Nishimura S., and Ihara M. Endocrinology 141 (2000) 1011
13. Mashiko S., Ishihara A., Iwaasa H., Sano H., Oda Z., Ito J., Yumoto M., Okawa M., Suzuki J., Fukuroda T., Jitsuoka M., Morin N.R., MacNeil D.J., Van der Ploeg L.H.T., Ihara M., Fukami T., and Kanatani A. Endocrinology 144 (2003) 1793
14. Dax S.L. Drugs Fut. 27 (2002) 273
15. Levens N.R., and Della-Zuana O. Curr. Opin. Invest. Drugs 4 (2003) 1198
16. Ishihara A., Moriya M., MacNeil D.J., Fukami T., and Kanatani A. Expert Opin. Ther. Pat. 16 (2006) 1701
17. Erondu N., Gantz I., Musser B., Suryawanshi S., Mallick M., Addy C., Cote J., Bray G., Fujioka K., Bays H., Hollander P., Sanabria-Bohórquez S.M., Eng W., Långström B., Hargreaves R.J., Burns D.J., Kanatani A., Fukami T., MacNeil D.J., Gottesdiener K.M., Amatruda J.M., Kaufman K.D., and Heymsfield S.B. Cell Metab. 4 (2006) 275
18. Sato N., Ando M., Ishikawa S., Jitsuoka M., Nagai K., Takahashi H., Sakuraba A., Tsuge H., Kitazawa H., Hirayama M., Iwaasa H., Mashiko S., Gomori A., Moriya R., Fujino N., Ohe T., Ishihara A., Kanatani A., and Fukami T. J. Med. Chem. 52 (2009) 3385
19. Liu G., Cogan D.A., and Ellman J.A. J. Am. Chem. Soc. 119 (1997) 9913
20. Caron S., Do N.M., and Sieser J.E. Tetrahedron Lett. 41 (2000) 2299
21. Feeley W.E., and Beavers E.M. J. Am. Chem. Soc. 81 (1959) 4004
22. Taylor Jr. E.C., and Driscoll J.S. J. Org. Chem. 25 (1960) 1716
23. Sato T., Yoshimatsu K., and Otera J. Synlett (1995) 845
24. Ando M., Wada T., and Sato N. Org. Lett. 8 (2006) 3805
25. Hirokawa Y., Horikawa T., and Kato S. Chem. Pharm. Bull. 48 (2000) 1847
26. Bastero A., Claver C., Ruiz A., Castillón S., Daura E., Bo C., and Zangrando E. Chem. Eur. J. 10 (2004) 3747
27. Whelan B., Iriepa I., and Galvez E. Synthesis (1994) 832
28. 125I]PYY binding assay, see Ref. 16.
29. Shibata Y., Takahashi H., and Ishii Y. Drug Metab. Dispos. 28 (2000) 1518
30. For experimental details describing the determination of the transcellular transport ratio (B-to-A/A-to-B ratio), see:. Ohe T., Sato M., Tanaka S., Fujino N., Hata M., Shibata Y., Kanatani A., Fukami T., Yamazaki M., Chiba M., and Ishii Y. Drug Metab. Dispos. 31 (2003) 1251
31. For experimental details for the functional assay, see Ref. 16.
32. Butcher, J. W.; Claremon, D. A.; Connolly, T. M.; Dean, D. C.; Karczewski, J.; Koblan, K. S.; Kostura, M. J.; Liverton, N. J.; Melillo, D. G. Radioligand and Binding Assay. World Patent Application WO 02/05860, 2002.
33. Binding affinities for human Y1, Y2, and Y4 receptors were determined as described in:. Kanatani A., Ishihara A., Iwassa H., Nakamura K., Okamoto O., Hidaka M., Ito J., Fukuroda T., MacNeil D.J., Van der Ploeg L.H.T., Fukami T., and Ihara M. Biochem. Biophys. Res. Commun. 272 (2000) 169
34. For the experimental details of the pharmacokinetic studies, see Ref. 16.
35. For the experimental details of the agonist-induced food intake study, see Ref. 16.